Alana Aragón-Herrera, Sandra Moraña-Fernández, Manuel Otero-Santiago, Laura Anido-Varela, Manuel Campos-Toimil, Javier García-Seara, Ana Román, José Seijas, Lucía García-Caballero, Javier Rodríguez, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Ricardo Lage, Oreste Gualillo, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Francisca Lago
The pharmacological inhibition of sodium-glucose cotransporter 2 (SGLT2) has emerged as a treatment for patients with type 2 diabetes mellitus (T2DM), cardiovascular disease and/or other metabolic disturbances, although some of the mechanisms implicated in their beneficial effects are unknown. The SGLT2 inhibitor (SGLT2i) empagliflozin has been suggested as a regulator of adiposity, energy metabolism, and systemic inflammation in adipose tissue. The aim of our study was to evaluate the impact of a 6-week-empagliflozin treatment on the lipidome of visceral (VAT) and subcutaneous adipose tissue (SAT) from diabetic obese Zucker Diabetic Fatty (ZDF) rats using an untargeted metabolomics approach...
March 15, 2023: Biomedicine & Pharmacotherapy